Epigral Limited has submitted a regulatory filing to the National Stock Exchange of India Limited (NSE) and BSE Limited. The purpose of the filing is to intimate the exchanges about a scheduled one-on-one meeting with an investor/analyst.

The meeting is scheduled with Kitara Capital. It is set to take place on Friday, 20th November 2026. The mode of the meeting will be Video Conferencing (V.C.).

The disclosure is made pursuant to the company's obligations under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company explicitly states that no unpublished price sensitive information (UPSI) will be shared or discussed during this interaction.

The filing includes a note that the scheduled meeting is subject to change due to exigencies on the part of either the Institutional Investors or the Company.

The letter is signed by Maulik Jayantibhai Patel, Managing Director (DIN:02006947), and is digitally timestamped on 2026.11.17 at 23:05:24 +05'30'.

Financial / Operational Impact

No financial or operational impact is disclosed. The filing is a procedural intimation of a non-deal roadshow meeting.